FierceBiotechOriginal article
{"a":[{"_":"Autobahn races toward pivotal trial after thyroid hormone mimic eases bipolar depression in ph. 2","$":{"href":"/biotech/autobahn-races-toward-pivotal-trial-after-thyroid-hormone-mimic-eases-bipolar-depression-ph","hreflang":"en"}}]}
Phase 2positivePositive
AI Analysis
Summary
Autobahn Therapeutics' thyroid hormone receptor stimulator demonstrated positive Phase 2 results by reducing depression severity in bipolar disorder patients, positioning the company to advance to late-stage development.
Clinical Trial Data
Phase
2
Primary Endpoint
Met
Outcome Details
thyroid hormone receptor stimulator successfully reduced depression severity in patients with bipolar disorder
Importance:7/10
Sentiment:
0.75
phase 2 databipolar disorderdepressionthyroid hormone receptorclinical trial
Read the original article
Published by FierceBiotech on June 4, 2026 10:44 AM